



# NOVAN

Nitric Oxide-Based Medicine

## Why Novan, Why Now

*A world leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies*

Clinically proven NITRICIL™ technology platform allows stable, tunable, and targeted delivery of therapeutic quantities of nitric oxide (NO)

Robust body of data with nearly 4,000 treated subjects supporting anti-microbial and anti-bacterial properties

Potential to address multi-billion dollar U.S. market

### THREE NDAs PLANNED OVER THREE YEARS

Product Candidate	Indication	Pre-IND	Phase 1	Phase 2	Phase 3	Approval	NDA Submission Targeted
DERMATOLOGY							
SB206	Molluscum						Q3 2022
SB204	Acne Vulgaris						2024 <sup>1</sup>
INFECTIOUS DISEASE							
SB019	SARS-CoV-2						2024 <sup>1</sup>

1. Company has expected cash runway into Q4 2022.

# 01


## SB206 Molluscum Contagiosum

*Positive topline  
results from pivotal  
Phase 3 with NDA  
submission targeted  
Q3 2022*

Prevalence rate in  
children 0-16 years old is  
**5.1%-11.5%**<sup>1</sup> in the U.S.

U.S. addressable market  
of **~6 million**<sup>2</sup>

### PIVOTAL PHASE 3: PRIMARY EFFICACY ENDPOINT AT WEEK 12



1. Prevalence in the US of 5.1% to 11.5% in children aged 0-16 years. (Fam Pract. 2014 Apr;31(2):130-6).

2. Molluscum Contagiosum - Epidemiology Forecast – 2028. Seven Major Markets (U.S., Germany, Spain, Italy, France, the United Kingdom, and Japan from 2017 – 2028).

Note: Two previously completed Phase 3 studies posted directionally similar results and one or both will be included in the NDA submission as confirmatory to the above, B-SIMPLE4 efficacy results.

# 02

## SB204 Acne Vulgaris

*Late-stage asset with  
two completed Phase  
3 studies*

**~50 Million**  
people with acne in  
the U.S.<sup>1</sup>

Topical U.S. acne market  
(products and combos)  
is approximately  
**\$2.9 Billion**<sup>2</sup>

Same active pharmaceutical ingredient as  
used in SB206 for molluscum yet formulated  
specifically for acne

Potential advantages over other topical  
therapies for the most common form of acne

Excellent local tolerability and favorable  
safety profile

1. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology 2006;55:490-500.

2. IMS National Prescription Audit - MAT Feb. 2016 - Acne Prescription Market TRx Dollars - MAT Feb 2016

# 03

## SB019 COVID-19

*Phase 1 in healthy  
volunteers in 1H 2022*

Strong preclinical and clinical data demonstrate anti-viral effect of berdazimer sodium  
against multiple viruses

*In vitro* and *in vivo* studies have demonstrated anti-viral effect of berdazimer sodium  
against SARS-CoV-2

Public health need to reduce breakthrough infections and transmission

Intranasal administration of SB019 may reduce viral burden in the nasal epithelium  
and lead to reduced transmission, disrupted disease progression, and alleviated  
symptoms